SG11201900606VA - Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders - Google Patents
Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disordersInfo
- Publication number
- SG11201900606VA SG11201900606VA SG11201900606VA SG11201900606VA SG11201900606VA SG 11201900606V A SG11201900606V A SG 11201900606VA SG 11201900606V A SG11201900606V A SG 11201900606VA SG 11201900606V A SG11201900606V A SG 11201900606VA SG 11201900606V A SG11201900606V A SG 11201900606VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- masp
- rule
- avenue
- compositions
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000037765 diseases and disorders Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 101001055956 Homo sapiens Mannan-binding lectin serine protease 1 Proteins 0.000 abstract 4
- 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108010078015 Complement C3b Proteins 0.000 abstract 1
- 229920000392 Zymosan Polymers 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F17/00—Compounds of rare earth metals
- C01F17/20—Compounds containing only rare earth metals as the metal element
- C01F17/206—Compounds containing only rare earth metals as the metal element oxide or hydroxide being the only anion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/77—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/77—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals
- C09K11/7728—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals containing europium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
- H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
- H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/50—Solid solutions
- C01P2002/52—Solid solutions containing elements as dopants
- C01P2002/54—Solid solutions containing elements as dopants one element only
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/80—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
- C01P2002/84—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by UV- or VIS- data
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
VehiclePBS) mAb mAb 13B1 300 250 200 150 100 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 111111111111011010101111101111010111101 0111001HOHNOVE# (10) International Publication Number WO 2018/026722 A8 08 February 2018 (08.02.2018) WI PO I PCT 8/0 267 22 A8 (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/40 (2006.01) A61K 45/06 (2006.01) (21) International Application Number: PCT/US2017/044714 (22) International Filing Date: 31 July 2017 (31.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/369,674 01 August 2016 (01.08.2016) US 62/419,420 08 November 2016 (08.11.2016) US 62/478,336 29 March 2017 (29.03.2017) US (71) Applicants: OMEROS CORPORATION [US/US]; 201 Elliott Avenue West, Seattle, WA 98119 (US). UNIVERSI- TY OF LEICESTER [GB/GB]; University Road, Leices- ter, LE1 7RH (GB). (72) Inventors: CUMMINGS, W., Jason; 3503 109th Place Northeast #1, Bellevue, WA 98004 (US). DEMOPU- LOS, Gregory, A.; 4845 Forest Avenue SE, Mercer Is- land, WA 98040 (US). DUDLER, Thomas; 13410 NE 36th Street, Bellevue, WA 98005 (US). SCHWAEBLE, Hans-Wilhelm; 36 The Green, Mountsorrel LE12 7AF (GB). TJOELKER, Larry, W.; 11731 Northeast 145th Street, Kirkland, WA 98034 (US). WOOD, Christi, L.; 19409 Broadway Avenue, Snohomish, WA 98296 (US). YABUKI, Munehisa; 722 North 88th Street, Seattle, WA 98103 (US). (74) Agent: QUINTON, Tineka; Omeros Corporation, 201 El- liott Avenue West, Seattle, WA 98119 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: COMPOSITIONS AND METHODS OF INHIBITING MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS FIG. 58 MASP-3 mAbs inhibit the APC in vivo C3/C3b/iC3b Deposition on Zymosan 1-1 O ei (57) : The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in c inhibiting the adverse effects of MASP-3 dependent complement activation. [Continued on next page] WO 2018/026722 A8 IMEDIM01101DEIREI01001111111111111101111111111111111111410# SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (48) Date of publication of this corrected version: 27 December 2018 (27.12.2018) (15) Information about Correction: see Notice of 27 December 2018 (27.12.2018)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369674P | 2016-08-01 | 2016-08-01 | |
| US201662419420P | 2016-11-08 | 2016-11-08 | |
| US201762478336P | 2017-03-29 | 2017-03-29 | |
| PCT/US2017/044714 WO2018026722A1 (en) | 2016-08-01 | 2017-07-31 | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900606VA true SG11201900606VA (en) | 2019-02-27 |
Family
ID=61073545
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010279YA SG10202010279YA (en) | 2016-08-01 | 2017-07-31 | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders |
| SG11201900606VA SG11201900606VA (en) | 2016-08-01 | 2017-07-31 | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders |
| SG10202010277SA SG10202010277SA (en) | 2016-08-01 | 2017-07-31 | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010279YA SG10202010279YA (en) | 2016-08-01 | 2017-07-31 | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010277SA SG10202010277SA (en) | 2016-08-01 | 2017-07-31 | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US10639369B2 (en) |
| EP (1) | EP3490603A4 (en) |
| JP (3) | JP6971306B2 (en) |
| KR (3) | KR102553777B1 (en) |
| CN (4) | CN116333147A (en) |
| AU (4) | AU2017306069B2 (en) |
| CA (3) | CA3031980C (en) |
| CL (3) | CL2019000230A1 (en) |
| CO (1) | CO2019001212A2 (en) |
| CR (1) | CR20190105A (en) |
| CU (1) | CU24568B1 (en) |
| EC (1) | ECSP19015192A (en) |
| GE (1) | GEP20247593B (en) |
| IL (3) | IL298690B2 (en) |
| JO (6) | JOP20170154B1 (en) |
| MA (1) | MA45798A (en) |
| MX (3) | MX2019000965A (en) |
| NZ (1) | NZ775767A (en) |
| PE (1) | PE20190389A1 (en) |
| PH (1) | PH12019500204A1 (en) |
| SA (1) | SA519400950B1 (en) |
| SG (3) | SG10202010279YA (en) |
| TW (4) | TW202214689A (en) |
| UA (1) | UA124674C2 (en) |
| UY (1) | UY37349A (en) |
| WO (1) | WO2018026722A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| CN110603252A (en) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| US20190038623A1 (en) | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria |
| EP3814374A4 (en) * | 2018-05-25 | 2022-03-09 | Achillion Pharmaceuticals, Inc. | Complement alternative pathway-associated nephropathy biomarkers |
| WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| CA3111810A1 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Morphic forms of dancopan |
| US11807627B2 (en) | 2018-09-25 | 2023-11-07 | Achillon Pharmaceuticals, Inc. | Morphic forms of complement factor D inhibitors |
| CN110244053B (en) * | 2019-05-09 | 2022-03-11 | 北京大学第三医院（北京大学第三临床医学院） | Molecular marker for diagnosing lupus nephritis and pulmonary hypertension disease and application thereof |
| CN112812182B (en) * | 2019-11-15 | 2023-01-06 | 深圳宾德生物技术有限公司 | FGFR 4-targeted single-chain antibody, chimeric antigen receptor T cell, and preparation method and application thereof |
| JP2023511189A (en) * | 2020-01-21 | 2023-03-16 | 上海柏全生物科技有限公司 | SEMG2 Antibodies and Uses Thereof |
| KR20230047492A (en) * | 2020-08-18 | 2023-04-07 | 오메로스 코포레이션 | Monoclonal antibodies, compositions and methods for detection of complement factor D |
| CN112950324B (en) * | 2021-03-15 | 2022-06-03 | 重庆邮电大学 | Knowledge graph assisted pairwise sorting personalized merchant recommendation method and system |
| CN115304670B (en) * | 2021-05-07 | 2024-07-30 | 华南农业大学 | Murine monoclonal antibody of feline coronavirus nucleocapsid protein, encoding gene and application thereof |
| US20230416406A1 (en) * | 2022-03-10 | 2023-12-28 | Omeros Corporation | Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease |
| WO2024097163A1 (en) * | 2022-11-02 | 2024-05-10 | Omeros Corporation | Therapeutic methods and uses for antibodies to human masp-3 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| JP3218637B2 (en) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | Stable aqueous liposome suspension |
| JP2958076B2 (en) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same |
| WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US7273925B1 (en) | 1998-12-15 | 2007-09-25 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
| US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| CA2391402A1 (en) | 1999-12-02 | 2001-06-07 | Jens Christian Jensenius | Masp-3, a complement-fixing enzyme, and uses for it |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| ES2601143T3 (en) | 2002-07-19 | 2017-02-14 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods thereof, and hydrogels and biomaterials prepared therefrom. |
| NZ538384A (en) | 2002-09-06 | 2009-04-30 | Alexion Pharma Inc | Treatment for asthma using a compound which binds to or otherwise blocks the generation and/or activity of one or more complement components reptors, such as, C5a receptors |
| US20060140939A1 (en) | 2003-02-21 | 2006-06-29 | Fung Sek C M | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| DE102004017370A1 (en) | 2004-04-08 | 2005-10-27 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | PUFA-PKS Genes from Ulkenia |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| MY169746A (en) | 2005-08-19 | 2019-05-14 | Abbvie Inc | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| JP5537420B2 (en) | 2007-05-31 | 2014-07-02 | ユニヴァーシティ オブ ワシントン | Inducible mutagenesis of target genes |
| WO2011006982A2 (en) | 2009-07-17 | 2011-01-20 | Rigshospitalet | Inhibitors of complement activation |
| CN102574915B (en) * | 2009-08-06 | 2014-10-22 | 伊缪纳斯制药株式会社 | Antibodies that specifically bind to A beta oligomers and use thereof |
| CA2780713A1 (en) * | 2009-09-03 | 2011-03-10 | Vancouver Biotech Ltd. | Monoclonal antibodies against gonadotropin-releasing hormone receptor |
| KR101647871B1 (en) * | 2010-03-05 | 2016-08-11 | 에프. 호프만-라 로슈 아게 | Antibodies against human csf-1r and uses thereof |
| US20120122107A1 (en) | 2010-11-16 | 2012-05-17 | Aarhus Universitet | Homeostatic multidomain protein, and uses for it |
| CN107011443B (en) * | 2011-05-04 | 2021-04-30 | 奥默罗斯公司 | Compositions for inhibiting MASP-2 dependent complement activation |
| RU2018114903A (en) * | 2012-04-06 | 2019-03-04 | Омерос Корпорейшн | COMPOSITIONS AND METHODS FOR INHIBITING MASP-1, AND / OR MASP-2, AND / OR MASP-3 FOR THE TREATMENT OF PAROXISMAL NIGHT HEMOGLOBINURIA |
| EP4119577A3 (en) * | 2012-06-18 | 2023-11-08 | Omeros Corporation | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
| RU2708032C2 (en) * | 2013-02-20 | 2019-12-03 | Новартис Аг | CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY |
| EP2970453B1 (en) * | 2013-03-13 | 2019-12-04 | Prothena Biosciences Limited | Tau immunotherapy |
| EP3099719B1 (en) * | 2014-01-29 | 2020-04-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
-
2017
- 2017-07-03 JO JOP/2017/0154A patent/JOP20170154B1/en active
- 2017-07-30 TW TW110149485A patent/TW202214689A/en unknown
- 2017-07-30 TW TW112116731A patent/TW202334243A/en unknown
- 2017-07-30 TW TW106125649A patent/TWI756248B/en active
- 2017-07-30 TW TW110149487A patent/TWI820555B/en active
- 2017-07-31 NZ NZ775767A patent/NZ775767A/en unknown
- 2017-07-31 CA CA3031980A patent/CA3031980C/en active Active
- 2017-07-31 CU CU2019000006A patent/CU24568B1/en unknown
- 2017-07-31 IL IL298690A patent/IL298690B2/en unknown
- 2017-07-31 MX MX2019000965A patent/MX2019000965A/en unknown
- 2017-07-31 US US15/665,030 patent/US10639369B2/en active Active
- 2017-07-31 CR CR20190105A patent/CR20190105A/en unknown
- 2017-07-31 EP EP17837477.3A patent/EP3490603A4/en active Pending
- 2017-07-31 SG SG10202010279YA patent/SG10202010279YA/en unknown
- 2017-07-31 CN CN202210980626.8A patent/CN116333147A/en active Pending
- 2017-07-31 IL IL298689A patent/IL298689B2/en unknown
- 2017-07-31 CN CN202210979606.9A patent/CN116333146A/en active Pending
- 2017-07-31 CA CA3122348A patent/CA3122348A1/en active Pending
- 2017-07-31 SG SG11201900606VA patent/SG11201900606VA/en unknown
- 2017-07-31 UA UAA201902009A patent/UA124674C2/en unknown
- 2017-07-31 JP JP2019505253A patent/JP6971306B2/en active Active
- 2017-07-31 MA MA045798A patent/MA45798A/en unknown
- 2017-07-31 KR KR1020227010749A patent/KR102553777B1/en active IP Right Grant
- 2017-07-31 KR KR1020197005706A patent/KR102382804B1/en active IP Right Grant
- 2017-07-31 AU AU2017306069A patent/AU2017306069B2/en active Active
- 2017-07-31 CN CN202210979607.3A patent/CN116327918A/en active Pending
- 2017-07-31 WO PCT/US2017/044714 patent/WO2018026722A1/en active Application Filing
- 2017-07-31 SG SG10202010277SA patent/SG10202010277SA/en unknown
- 2017-07-31 IL IL264592A patent/IL264592B2/en unknown
- 2017-07-31 KR KR1020227010743A patent/KR102624948B1/en active IP Right Grant
- 2017-07-31 GE GEAP201715019A patent/GEP20247593B/en unknown
- 2017-07-31 CN CN201780047995.9A patent/CN109715209B/en active Active
- 2017-07-31 PE PE2019000261A patent/PE20190389A1/en unknown
- 2017-07-31 CA CA3173979A patent/CA3173979A1/en active Pending
- 2017-08-01 UY UY0001037349A patent/UY37349A/en active IP Right Grant
-
2019
- 2019-01-22 MX MX2023000482A patent/MX2023000482A/en unknown
- 2019-01-22 MX MX2023000525A patent/MX2023000525A/en unknown
- 2019-01-23 SA SA519400950A patent/SA519400950B1/en unknown
- 2019-01-28 PH PH12019500204A patent/PH12019500204A1/en unknown
- 2019-01-29 CL CL2019000230A patent/CL2019000230A1/en unknown
- 2019-02-12 CO CONC2019/0001212A patent/CO2019001212A2/en unknown
- 2019-02-28 EC ECSENADI201915192A patent/ECSP19015192A/en unknown
-
2020
- 2020-04-01 US US16/837,600 patent/US10745274B1/en active Active
- 2020-06-23 US US16/909,578 patent/US11027015B2/en active Active
- 2020-07-08 AU AU2020204551A patent/AU2020204551B2/en active Active
- 2020-10-06 AU AU2020250188A patent/AU2020250188B2/en active Active
-
2021
- 2021-04-27 US US17/241,628 patent/US11883493B2/en active Active
- 2021-11-01 JP JP2021178521A patent/JP7350821B2/en active Active
- 2021-11-01 JP JP2021178522A patent/JP7350822B2/en active Active
-
2022
- 2022-10-03 JO JOP/2022/0241A patent/JOP20220241A1/en unknown
- 2022-10-03 JO JOP/2022/0242A patent/JOP20220242A1/en unknown
- 2022-10-03 JO JOP/2022/0244A patent/JOP20220244A1/en unknown
- 2022-10-03 JO JOP/2022/0243A patent/JOP20220243A1/en unknown
- 2022-10-03 JO JOP/2022/0245A patent/JOP20220245A1/en unknown
- 2022-10-17 AU AU2022256090A patent/AU2022256090B2/en active Active
-
2023
- 2023-11-29 US US18/523,203 patent/US20240342278A1/en active Pending
-
2024
- 2024-03-21 CL CL2024000824A patent/CL2024000824A1/en unknown
- 2024-03-21 CL CL2024000823A patent/CL2024000823A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900606VA (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| SG11201901444PA (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
| SG11201909547TA (en) | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201908947QA (en) | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201408261UA (en) | Syringe | |
| SG11201803834UA (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios |